CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing division of Cenra Inc., today announced that the companies have entered into a joint agreement to: announced that it had concluded. Co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine Spikevax®.
Under the agreement, Moderna will manufacture and sell mRNA respiratory vaccines. Cenra Healthcare will engage in promotional efforts and conduct medical education activities to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The initial term of the agreement is until July 31, 2027, and financial details of the agreement have not been disclosed.
“We are very pleased to partner with Senra Healthcare, a trusted leader in Taiwan's medical industry with extensive expertise in infectious disease and respiratory products,” said Joyce Lee, general manager of Moderna Taiwan. said. “Their strong presence in the market will help ensure broader access to our vaccines. We are committed to advancing public health efforts across Taiwan and we are excited about this partnership. This will enable us to expand our educational efforts around our COVID-19 vaccine and future portfolio, particularly towards vaccine development.''Respiratory diseases continue to be a global threat. ”
“At Cenra, we are proud and excited to partner with a global innovator like Moderna to contribute to Taiwan's public health efforts,” said Lucas Lin, General Manager of Cenra Healthcare. “In addition to our industry-leading market presence and deep understanding of Taiwan's healthcare landscape, Cenra Healthcare is confident that Moderna's world-class mRNA vaccine will ensure access through seamless collaboration with healthcare providers and communities. This makes us well-equipped to support Taiwan's vaccination program.”
About Moderna
Moderna is a founding leader in the field of mRNA medicine. Through advancements in mRNA technology, Moderna is rethinking the way medicines are made and transforming the way we treat and prevent disease for everyone. The company has worked at the intersection of science, technology, and health for more than a decade, resulting in unprecedented speed and progress, including one of the earliest and most effective COVID-19 vaccines. We have developed medicines with efficiency.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. Moderna has a unique culture and global team, rooted in Moderna's values and mindset to responsibly transform the future of human health, and is committed to making the greatest impact possible on people through mRNA medicines. . For more information about Moderna, visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube, and LinkedIn.
story continues
About Senra Healthcare
Founded in 2004 as the sales and marketing arm of Cenra Inc., Cenra Healthcare is a leader in providing comprehensive healthcare solutions tailored to meet the diverse needs of individuals in Taiwan and abroad. Cenra Healthcare specializes in the distribution of quality medicines and innovative healthcare products, ensuring accessibility and affordability for all.
Founded in 1952, Cenra Inc. is one of Taiwan's leading healthcare companies, with its subsidiaries and affiliates offering a wide range of human and veterinary drugs, active pharmaceutical ingredients, dietary supplements, and over-the-counter (OTC) products. Covers the field. Pharmaceuticals, household and beauty products, and elderly care services. With a vision of “strengthening health equity and promoting a healthier world for all,” Cenra delivers impactful health solutions and strengthens public health through partnerships and strategic alliances. I'm working on doing that. For more information, please visit cenra.com.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: and the Company's ability to secure broad access to Moderna's mRNA respiratory portfolio throughout Taiwan. Forward-looking statements in this press release are not promises or guarantees. These forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna's control. Don't rely on it too much. Therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the heading “Risk Factors” in Moderna's Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings. involves risks and uncertainties. Moderna and the Securities and Exchange Commission are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna contact information
media:
luke milsey willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com
Investor:
Ravina Talukdar
Senior Vice President and Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
senra contact
media:
Tiffany Chen
Director Corporate Affairs & Communications
Tiffany.chen@cenra.com
Source: Moderna
